| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6063467 | Journal of Allergy and Clinical Immunology | 2015 | 9 Pages |
Abstract
The established within-patient MID for the ACQ and AQLQ is not achievable as a group-wise efficacy threshold between treatment arms in clinical studies in which controllers are added to ICS treatment. Thus in addition to reporting mean changes of the instruments, other measurement criteria should be considered, including responder analyses.
Keywords
ACQICSAQLQMTCRCTMIDLTRAQuality of lifeRandomized controlled trialAsthmaLeukotriene receptor antagonistLong-acting β-agonistMinimal important differenceLABANetwork meta-analysismixed treatment comparisonpatient-reported outcomePROQuestionnaireAsthma Control QuestionnaireAsthma Quality of Life QuestionnaireAsthma controlInhaled corticosteroid
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Eric D. MD, Dirk PhD, Costel PhD, Maria PhD, MBA, Andy MD, Petra MD, J. Mark MD,